Herbert Loong: Look forward to fruitful discussions and exchanges on lung cancer screening in the Asia Pacific region

Herbert Loong shared a post by Lung Cancer Policy Network on LinkedIn, adding the following:

“We look forward to fruitful discussions and exchanges highlighting issues surrounding implementation of lung cancer screening in the Asia Pacific region where there are key differences in epidemiology, healthcare access and infrastructure between and within countries and regions in our locality. Come join us in the run up to our In Person event to be held at ACLC24 in Hong Kong!”

Quoting Lung Cancer Policy Network’s post:

“Join us and Asia Pacific Coalition against Lung Cancer on 25 September 2024, 16.00–17.00 HKT (18.00–19.00 AEST, 10.00–11.00 CEST) for an exciting webinar on the current landscape of screening programmes for lung cancer in the Asia-Pacific region.

The region faces a unique set of challenges in the epidemiology of lung cancer, risk factors for the disease and varied health systems, all operating within a range of economic and social contexts. These factors should be considered when preparing and implementing screening programmes for lung cancer.

The webinar will feature screening and health system leaders from across the region. These experts will outline the current stage of lung cancer screening in Australia, Singapore, South Korea and India, sharing some of the challenges experienced and lessons learnt so far.

Register now.”

Source: Herbert Loong/LinkedIn and Lung Cancer Policy Network/LinkedIn

Dr. Herbert H. F. Loong holds several prominent positions in oncology. He is the Chair-Elect of the International Affairs Committee, a Scientific Track Member (2022-2024), and the Track Leader for Sarcoma (2023) at the American Society of Clinical Oncology (ASCO).

Additionally, he has been promoted to Steering Committee Member at the Lung Cancer Policy Network. Dr. Loong is also the Chairperson of the Asia Pacific Coalition against Lung Cancer, a Board Member of the Connective Tissue Oncology Society, and a Committee Member of the International Association for the Study of Lung Cancer. He is an Associate Professor in the Department of Clinical Oncology at The Chinese University of Hong Kong (CUHK).